Unicycive Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell UNCY and other ETFs, options, and stocks.About UNCY
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220.
CEOShalabh Gupta
CEOShalabh Gupta
Employees22
Employees22
HeadquartersLos Altos, California
HeadquartersLos Altos, California
Founded2016
Founded2016
Employees22
Employees22
UNCY Key Statistics
Market cap74.00M
Market cap74.00M
Price-Earnings ratio-1.24
Price-Earnings ratio-1.24
Dividend yield—
Dividend yield—
Average volume662.78K
Average volume662.78K
High today$4.35
High today$4.35
Low today$4.16
Low today$4.16
Open price$4.25
Open price$4.25
Volume410.27K
Volume410.27K
52 Week high$11.00
52 Week high$11.00
52 Week low$2.83
52 Week low$2.83
UNCY News
TipRanks 5d
Unicycive Faces Securities Lawsuit Over Drug ClaimsElevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
TipRanks 6d
Unicycive Therapeutics granted new U.S. patent for UNI-494 to treat CKDUnicycive Therapeutics (UNCY) announced the issuance of U.S. Patent 12,377,082 by the U.S. Patent and Trademark Office for UNI-494 to treat Chronic Kidney Disea...
Analyst ratings
100%
of 7 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own UNCY. This list is generated using Robinhood data, and it’s not a recommendation.